By Genetic Engineering and Biotechnology News
Clinical trial results are showing the first successes against solid tumors for CAR-T cells. The findings offer hope for children with a group of deadly brain and spinal cord tumors, including a cancer called diffuse intrinsic pontine glioma, or DIPG. The immune-cell therapy shrank children’s brain tumors, restored neurologic function and—for one participant—erased all detectable traces of a brain cancer typically considered incurable.
The findings are published in Nature in the paper, “Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas.”
Of the 11 participants who received CAR-T cells in the trial, nine showed benefits and had functional improvement in the disabilities caused by their disease.
